Natural Brain Protein SORLA May Halt Alzheimer's and Reverse Memory Decline

A recent study has revealed that a naturally occurring protein in the brain could serve as a strong defense against the damage caused by Alzheimer's disease.

Scientists at the Sanford Burnham Prebys Medical Discovery Institute in California found that increasing levels of a protein called SORLA can significantly inhibit the toxic protein tangles associated with neurodegenerative disease, opening new possibilities for effective treatments of this challenging disorder.

The Role of SORLA in Neuroprotection

SORLA is a complex and essential protein primarily present in the central nervous system. It is produced by the body and cannot be obtained from external sources such as supplements or food.

In Alzheimer's disease, another protein known as tau detaches from its normal role in maintaining brain structure and stability. Instead, it forms abnormal clumps called tau tangles. These toxic aggregates destroy neural connections, trigger cell death, and lead to cognitive decline and progressive memory loss.

Insights into Alzheimer's Disease Mechanisms

Alzheimer's disease is characterized by a gradual decline in neural functions over time, resulting in brain shrinkage and loss of mental abilities. It is the most common cause of dementia, a broader term describing symptoms caused by physical brain damage, accounting for approximately 60% to 70% of all dementia cases worldwide.

While SORLA was previously known for its ability to reduce amyloid-beta protein accumulation—another hallmark of Alzheimer's alongside tau tangles—its impact on tau tangles remained unclear until now.

Experimental Findings from Genetically Modified Mice

The study, published in the journal Science Advances, involved genetically engineered mice designed to produce higher levels of human SORLA protein alongside tau tangles, simulating the human Alzheimer's condition.

Results demonstrated that elevated SORLA levels actively protect the brain against various biological triggers of neurodegeneration. Increased SORLA reduced tau hyperphosphorylation—a chemical process causing tau protein aggregation and tangling—and prevented abnormal tau spread across neural networks.

Mice with added SORLA exhibited significantly less brain shrinkage, reduced tau protein accumulation, and better preservation of synapses, the critical junctions enabling communication between brain cells. Conversely, mice completely lacking the gene responsible for SORLA production showed markedly worsened neurodegeneration and cellular damage, confirming the protein's fundamental protective role.

Potential for New Alzheimer's Therapies

Dr. Huiji Huang, a researcher at Sanford Burnham Prebys and the study's lead author, stated, "When SORLA protein levels increase, you can suppress the harmful effects present in tau protein diseases. We observed less brain atrophy and reduced tau accumulation, which was very exciting."

Dr. Timothy Huang, an assistant professor at the center and co-author, noted that these findings could pave the way for repurposing existing drugs to reverse disease symptoms, representing a significant shift in treatment strategies.

Although further research is necessary to translate these findings into safe and effective human therapies, the study provides a promising roadmap for treatments aimed at protecting memory and halting the neurodegenerative effects of Alzheimer's disease, which currently lacks a known cure.